

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-20. (Canceled)

21. (Currently Amended) ~~A polypeptide~~ An isolated polypeptide consisting of:

(i) a sequence corresponding to residues 163 to 199 of DP-1, said sequence being: KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1); or

(ii) a sequence corresponding to residues 163-199 of DP-1, said sequence being: KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), and said sequence further including from 1 to 5 amino acid residues at the N- or C-terminus thereof, where the presence of such residues has no significant effect on the function of the polypeptide.

22. (Currently Amended) ~~A fragment of a~~ An isolated polypeptide consisting of:

(i) ~~the sequence: KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), or~~

(ii) ~~the sequence:~~
of a first fragment of a sequence
KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), ~~said sequence further including~~ and a second fragment consisting of from 1 to 5 amino acid residues at joined to at least one of the N- or C-terminus of the first fragment thereof, where the

presence of the second fragment ~~such residues~~ has no significant effect on the function of the polypeptide;

which ~~fragment-polypeptide~~ is capable of antagonising the heterodimerisation of a DP protein with an E2F protein.

23. (Currently Amended) The polypeptide A-fragment according to claim 22 wherein said first fragment is ~~which comprises~~ the sequence NVLMAMNII (SEQ ID NO:2) or ALNVLMA (SEQ ID NO:7).

24. (Currently Amended) The polypeptide A-fragment according to ~~claim 23~~ which claim 22 wherein said first fragment is selected from the group consisting of:

RRRVYDALNVLMAMNIISK (SEQ ID NO:3);

NVLMAMNIISKEKKEIKWIG (SEQ ID NO:4);

RVYDALNVLMAMNIIS (SEQ ID NO:5); and

YDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:6).

25. (Currently Amended) An isolated variant ~~A-variant~~ of a polypeptide consisting of:

(i) a sequence corresponding to residues 163 to 199 of DP-1, said sequence being: KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), or

(ii) a sequence corresponding to residues 163 to 199 of DP-1, said sequence being: KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), and said

sequence further including from 1 to 5 amino acid residues at the N- or C-terminus thereof, where the presence of such residues has no significant effect on the function of the polypeptide;

said variant differing from the polypeptide by the presence of from 1 to 5 amino acid substitutions in the sequence of said polypeptide, said variant being capable of antagonising the heterodimerisation of a DP protein with an E2F protein.

26. (Currently Amended) The variant~~A variant~~ according to claim 25 wherein the substitutions include substitutions selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.

27. (Currently Amended) An isolated polypeptide which consists of A
~~polypeptide which comprises:~~

(i) a first portion having an amino acid sequence selected from the group consisting of:

- (a) KNIRRRVYDALNVLAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1),
- (b) NVLMAMNII (SEQ ID NO:2),
- (c) RRRVYDALNVLAMNIISK (SEQ ID NO:3),
- (d) NVLMAMNIISKEKKEIKWIG (SEQ ID NO:4),
- (e) RVYDALNVLAMNIIS (SEQ ID NO:5),
- (f) YDALNVLAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:6), and
- (g) ALNVLMA (SEQ ID NO:7); and

(ii) a second portion, attached to the N- or C-terminus of the first portion, which consists of ~~comprises~~ a sequence of amino acids not naturally contiguous to the first portion in DP-1.

28. (Previously Presented) A polypeptide according to claim 27 wherein the second portion is a membrane translocation sequence.

29. (Currently Amended) A polypeptide according to claim 28 wherein the membrane translocation sequence is a ~~is the~~ membrane translocation sequence of the *Drosophila melanogaster* antennapedia protein.

30. (Previously Presented) A composition comprising a polypeptide according to any one of claims 21 to 29 together with a pharmaceutically acceptable diluent or carrier.

31. (Previously Presented) A composition according to claim 30 which further comprises a cytostatic or cytotoxic agent.

32. (Previously Presented) A composition formulation comprising a polypeptide of SEQ ID NO:1 in the form of an orally, topically or parenterally administrable form.

33. (Withdrawn) A method of inducing apoptosis in a cell which comprises introducing into said cell an effective amount of a polypeptide according to claim 21.

34. (Withdrawn) A method according to claim 33 wherein said cell is a tumour cell.

35. (Withdrawn) A method according to claim 33 wherein said cell is a cardiovascular cell.

36. (Currently Amended) An isolated product ~~A product~~ comprising a polypeptide consisting of:

(i) a sequence corresponding to residues 163 to 199 of DP-1, said sequence being: KNIRRRVYDALNVLMMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1),
or

(ii) a sequence corresponding to residues 163 to 199 of DP-1, said sequence being: KNIRRRVYDALNVLMMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1),
and said sequence further including from 1 to 5 amino acid residues at the N- or C-terminus thereof, where the presence of such residues has no significant effect on the function of the polypeptide;

and a cytostatic or cytotoxic agent as a combined preparation.

37. (Withdrawn) A method of treating uncontrolled proliferation of cells in a human or animal body in need of said treating comprising administering a composition

of claim 31 to said human or animal body such that said uncontrolled proliferation of cells is treated.